Phenotype and molecular characterization of Wilson's disease in Morocco.
ATP7B gene
Genotype
Morocco
Phenotype
Prevalence
Wilson's disease
Journal
Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659
Informations de publication
Date de publication:
06 Apr 2024
06 Apr 2024
Historique:
received:
01
08
2022
revised:
29
01
2024
accepted:
29
03
2024
medline:
9
4
2024
pubmed:
9
4
2024
entrez:
8
4
2024
Statut:
aheadofprint
Résumé
In Morocco the prevalence of Wilson disease (WD) and the spectrum of mutations are not known. The aim of the present study was to estimate the prevalence of WD in Morocco, to evaluate the phenotype among a large cohort of WD patients, and to characterize ATP7B variants in a subgroup of WD patients. We collected data from 226 patients admitted to five university hospital centers in Morocco between 2008 and 2020. The diagnosis was based on clinical manifestations, function tests and biochemical parameters. The genotype was characterized in 18 families diagnosed at the University Hospital Center of Marrakesh, by next generation sequencing. The mean annual prevalence in Morocco was 3.88 per 100,000 and the allele frequency was 0.15%. Among the 226 patients included (121 males and 105 females), 196 were referred for a hepatic or neurological involvement and 30 were asymptomatic. The mean age at diagnosis was 13 ± 5.1 years (range: 5 - 42 years). Consanguinity was found in 63.3% of patients. The mean duration of illness was 2.8 ± 1.9 years. Kayser-Fleischer rings were found in 131 (67.9%) of 193 patients. Among the 196 symptomatic patients, 141/159 (88.7%) had low serum ceruloplasmin (<0.2g/L) and a high 24-hours urinary copper (>100μg/day) was found in 173/182 (95.1%) patients. The initial treatment was D-penicillamine in 207 patients, zinc acetate in five, zinc sulphate in five, and nine patients were not treated; 60/207 (29%) patients have stopped treatment. A total of 72 patients died; the mortality rate was 31.9%. Eight different ATP7B variants were identified among the 18 patients studied, of which two were novel (p.Cys1104Arg and p.Gln1277Hisfs*52), and six previously published (p.Gln289Ter, p.Cys305Ter, p.Thr1232Pro, p.Lys1020Arg, p.Glu583ArgfsTer25 and c.51+4A>T). All informative patients were homozygous for the disease-causing mutation. In Morocco, a high prevalence due to consanguinity and a high mortality rate due to the difficulty of diagnosis and lack of treatment were observed in WD patients. NGS sequencing identified new ATP7B variants in WD patients from Morocco.
Sections du résumé
BACKGROUND AND STUDY AIMS
OBJECTIVE
In Morocco the prevalence of Wilson disease (WD) and the spectrum of mutations are not known. The aim of the present study was to estimate the prevalence of WD in Morocco, to evaluate the phenotype among a large cohort of WD patients, and to characterize ATP7B variants in a subgroup of WD patients.
PATIENTS AND METHODS
METHODS
We collected data from 226 patients admitted to five university hospital centers in Morocco between 2008 and 2020. The diagnosis was based on clinical manifestations, function tests and biochemical parameters. The genotype was characterized in 18 families diagnosed at the University Hospital Center of Marrakesh, by next generation sequencing.
RESULTS
RESULTS
The mean annual prevalence in Morocco was 3.88 per 100,000 and the allele frequency was 0.15%. Among the 226 patients included (121 males and 105 females), 196 were referred for a hepatic or neurological involvement and 30 were asymptomatic. The mean age at diagnosis was 13 ± 5.1 years (range: 5 - 42 years). Consanguinity was found in 63.3% of patients. The mean duration of illness was 2.8 ± 1.9 years. Kayser-Fleischer rings were found in 131 (67.9%) of 193 patients. Among the 196 symptomatic patients, 141/159 (88.7%) had low serum ceruloplasmin (<0.2g/L) and a high 24-hours urinary copper (>100μg/day) was found in 173/182 (95.1%) patients. The initial treatment was D-penicillamine in 207 patients, zinc acetate in five, zinc sulphate in five, and nine patients were not treated; 60/207 (29%) patients have stopped treatment. A total of 72 patients died; the mortality rate was 31.9%. Eight different ATP7B variants were identified among the 18 patients studied, of which two were novel (p.Cys1104Arg and p.Gln1277Hisfs*52), and six previously published (p.Gln289Ter, p.Cys305Ter, p.Thr1232Pro, p.Lys1020Arg, p.Glu583ArgfsTer25 and c.51+4A>T). All informative patients were homozygous for the disease-causing mutation.
CONCLUSION
CONCLUSIONS
In Morocco, a high prevalence due to consanguinity and a high mortality rate due to the difficulty of diagnosis and lack of treatment were observed in WD patients. NGS sequencing identified new ATP7B variants in WD patients from Morocco.
Identifiants
pubmed: 38588792
pii: S2210-7401(24)00056-1
doi: 10.1016/j.clinre.2024.102335
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102335Informations de copyright
Copyright © 2024. Published by Elsevier Masson SAS.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: This work was supported by the Association pour le Développement de la Neurogénétique.